A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Anti-CD33 chimeric antigen receptor T cell therapy Yake Biotechnology (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 02 Apr 2025 New trial record